RenovaCare (RenovaCare) Interest Expense : $-0.00 Mil (TTM As of Sep. 2022)

View and export this data going back to . Start your Free Trial

What is RenovaCare Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. RenovaCare's interest expense for the three months ended in Sep. 2022 was $ -0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. RenovaCare's Operating Income for the three months ended in Sep. 2022 was $ -1.88 Mil. RenovaCare's Interest Expense for the three months ended in Sep. 2022 was $ -0.00 Mil. RenovaCare did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

RenovaCare Interest Expense Historical Data

The historical data trend for RenovaCare's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovaCare Interest Expense Chart

RenovaCare Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Interest Expense

Get a 7-Day Free Trial

-1.00

-0.14

RenovaCare Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

RenovaCare Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

RenovaCare (OTCPK:RCAR) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

RenovaCare's Interest Expense for the three months ended in Sep. 2022 was $-0.00 Mil. Its Operating Income for the three months ended in Sep. 2022 was $-1.88 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2022 was $0.80 Mil.

RenovaCare's Interest Coverage for the quarter that ended in Sep. 2022 is calculated as

RenovaCare did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

RenovaCare (RenovaCare) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovaCare Inc (OTCPK:RCAR) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

9375 East Shea Boulvard, Suite 107-A, Scottsdale, AZ, USA, 85260

Website

https://www.renovacareinc.com

RenovaCare Inc is a biotechnology company focusing on the acquisition, research, development and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The company's initial products under development target skin. It offers treatment methodology for cell isolation for the regeneration of human skin cells, along with a medical-grade liquid spraying device and associated equipment (the SkinGun). RenovaCare is evaluating the efficacy and potential of SkinGun, in combination with a cell isolation method, in the treatment of tissue that has been subject to severe trauma. Geographically all the activities are functioned through the region of United States.

Executives

Patsy Trisler	officer: Vice President	430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Thomas Bold	officer: President & CEO	430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Joseph Sierchio	director	430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Kenneth Kirkland	director	430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Rhonda Beth Rosen	director, officer: President & CEO	43 DICKINSON ROAD, BASKING RIDGE NJ 07920
1420525 Alberta Ltd.	10 percent owner	1628 WEST 1ST AVENUE, SUITE 216, VANCOUVER A1 V6J1G1
David E Jenkins	director	406 NORTH HERMOSA DRIVE, PALM SPRINGS CA 92262
Antonino G Cacace	director, officer: President	CRUD-Y-GWYNT, CASWELL BAY, SWANSEA X0 SA3 3BU
Jeet Sidhu	director	5667 SUNRISE CRESCENT WEST, SURREY, BC A1 V3S 7M4
Derek Cooper	officer: President/ CEO
Frank J Fabio	officer: CFO/Sec.(Resigned 1/9/2009)	670 BROADWAY, MASSAPEQUA NY 11758
Christian F Hudson	director	33 CHURCHILL ROAD, TENAFLY NJ 07670
Harmel S Rayat	director, 10 percent owner	700 - 688 WEST HASTINGS STREET, VANCOUVER A1 V6B 1P1
Stanley Wong	officer: President/CEO
Terri Dumoulin	director, officer: Secretary/Treasurer